echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > YP01001 Capsule, a subsidiary of Fosun Pharma, was approved to carry out clinical trials for advanced solid tumors

    YP01001 Capsule, a subsidiary of Fosun Pharma, was approved to carry out clinical trials for advanced solid tumors

    • Last Update: 2021-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 17, Fosun Pharma issued an announcement stating that recently, its holding subsidiary Chongqing Yaoyou Pharmaceutical Co.


    Chongqing Yaoyou plans to carry out a phase I clinical trial of the new drug in China (excluding Hong Kong, Macao and Taiwan regions, the same below) when the conditions are met in the near future.


    YP01001 capsule is an innovative small molecule chemical drug intended to treat advanced solid tumors; the preclinical development of YP01001 capsule is carried out by Fosun Pharma (including the company and its holding subsidiaries/units) and Shanghai WuXi AppTec New Drug Development Co.


    As of the date of this announcement, the same type of YP01001 capsules that have been marketed in China include Lenvatinib mesylate capsules.


    As of February 2021, Fosun Pharma has invested approximately RMB 33.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.